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Sigmoidoscopy screening for colorectal cancer
May reduce mortality, but longer term results are awaited
Evidence supporting colorectal screening, aside from 
randomised trials of faecal occult blood testing, comes 
mainly from observational studies. In the linked paper 
interim results of the Norwegian Colorectal Cancer 
Prevention (NORCCAP) trial are presented.1 NORC‑
CAP is one of three ongoing trials of once only screen‑
ing sigmoidoscopy.1‑3 The findings suggest that the 
intervention may be effective in reducing mortality 
from colorectal cancer. 
The NORCCAP trial randomised 55 736 people 
aged 55‑64 years to usual care or to once only flex‑
ible sigmoidoscopy with or without a single round 
of immunochemical faecal occult blood testing. The 
primary outcome for this first report is 7 year cumu‑
lative incidence of colorectal cancer (anywhere in 
the colon); the secondary outcome is 6 year mortal‑
ity from colorectal cancer. Colonoscopy, which was 
done in 21% of patients screened, was recommended 
for people with a positive screening result, defined as 
any polyp 10 mm or larger in diameter, any histolog‑
ically verified adenoma or carcinoma, or a positive 
faecal occult blood test. Follow‑up was obtained from 
the Cancer Registry of Norway and the Norwegian 
Cause of Death Registry, both of which are virtually 
100% complete.
Of 13 653 people invited for screening sigmoido‑scopy, 
8846 (65%) underwent sigmoidoscopy; 41 092 individu‑
als served as controls. The overall incidence of colorectal 
cancer did not differ significantly between screened and 
control groups (134.5 v 131.9 cases per 100 000 person 
years). The incidence of rectosigmoid cancer among 
attendees was reduced by 27% (58 v 79 per 100 000 
person‑years; P=0.10). The  intention‑to‑screen  analysis 
showed no significant difference in mortality from 
 colorectal cancer (hazard ratio 0.73; 95% confidence 
interval 0.47 to 1.13), while the per protocol analysis 
showed a significant reduction in mortality for any 
 colorectal cancer (0.41; 0.21 to 0.82) and for  rectosigmoid 
cancer (0.24; 0.08 to 0.76). Compared with the control 
and  non‑attending groups, people with screen detected 
colorectal cancer tended to have earlier stage disease and 
had a lower case‑fatality rate, though neither outcome 
was compared statistically.
 If the study and findings are accepted as rigorous 
and valid, what explains the lack of a difference in 
cumulative incidence of colorectal cancer between 
screened and control groups, and how important is 
this finding?
Previous data on sigmoidoscopy screening come 
largely from high quality case‑control studies suggest‑
ing a 60‑80% reduction in mortality from distal but not 
from proximal colorectal cancer.4 5 A case‑control study 
suggested that endoscopic procedures (sigmoidoscopy 
and colonoscopy) of the large bowel reduced incidence 
of colorectal cancer by 50% for up to six years.6 The 
Telemark clinical trial showed an 80% reduction in 
cancer incidence with sigmoidoscopy screening alone, 
but no effect on mortality from colorectal cancer, and 
an increase in all‑cause mortality, due mostly to cardio‑
vascular disease.7 The reduction in cancer incidence 
was observed after 13 years of follow‑up. Cumula‑
tively, these data suggest that sigmoidoscopy should 
be expected to reduce incidence and mortality related 
to colorectal cancer, at least for lesions within reach of 
the sigmoidoscope.
NORCCAP chose a high but appropriate bar by 
including the (prevalent) cancers initially detected by 
sigmoidoscopy in the measure of overall cumulative 
incidence. Excluding these prevalent cancers would 
have biased the results in favour of screening because 
of inability to exclude them in the unscreened control 
group. Using overall (as opposed to distal) incidence 
further raises the bar, since sigmoidoscopy would be 
expected to have a greater effect on incidence of distal 
cancers. With a smaller benefit on overall incidence 
expected, more time may be needed to detect it.
Since screening is expected to increase the detection 
of early stage curable cancer, we might expect a reduc‑
tion in cancer mortality to occur before the reduction 
in incidence that results from removal of adenomas. 
In a trial of annual guaiac‑based faecal occult blood 
test screening, a reduction in mortality from colorectal 
cancer was reported seven years earlier than a reduc‑
tion in incidence.8 9 Although the difference between 
the groups was not significant, the reduction in over‑
all mortality from colorectal cancer in NORCCAP is 
encouraging. The per protocol analyses more clearly 
indicate a reduction in mortality, but these findings 
may be prone to selection bias. Longer follow up will 
clarify these effects. 
What are the implications of the current findings? 
Since site specific cancer mortality is generally con‑
sidered the most appropriate end point for evaluating 
screening interventions,10 we should be encouraged 
by NORCCAP’s interim findings. Evidence to date 
strongly suggests that one time screening sigmoidos‑
copy can reduce incidence and mortality from distal 
colorectal cancer and may be a legitimate strategy. We 
await the further results of this landmark trial and of 
the other ongoing trials of sigmoidoscopy screening.
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Treatment of enteric fever
Fluoroquinolones remain the best option in areas where resistance is uncommon
Enteric fever (typhoid and paratyphoid), caused by 
S almonella enterica serovar Typhi or serovar Paratyphi 
A, represents a major burden of disease in commu‑
nities that lack clean water and adequate sanitation. 
More than 27 million cases of enteric fever occur 
worldwide each year, with 216 000 deaths.1 Com‑
munity based studies in Asia have shown a yearly 
incidence greater than 400/100 000 population in 
infants and children.2 In developed countries, return‑
ing travellers or those visiting friends and relatives in 
their family’s country of origin are at risk.3 In endemic 
areas, most patients are treated with oral antibiotics as 
outpatients, and only those with severe disease need 
hospital admission. Relapse may complicate the ill‑
ness, and faecal carriage can become chronic and 
lead to onward transmission. In the linked systematic 
review, Thaver and colleagues compare the effective‑
ness of fluoroquinolones as firstline agents with that of 
other antibiotics for treating enteric fever.4
Until the late 1980s, two to three weeks of chloram‑
phenicol was the treatment of choice for enteric fever. 
Plasmid mediated multidrug resistant (MDR) strains 
then emerged that were resistant to chloramphenicol, 
amoxicillin, and co‑trimoxazole.  Fluoroquinolones 
(ciprofloxacin and ofloxacin), extended spectrum 
cephalosporins (ceftriaxone and cefixime), and azithro‑
mycin were suitable alternatives for resistant organ‑
isms and five to 10 days of an oral fluoro‑quinolone 
became a widely used regimen.5
In areas where fluoroquinolones, such as cipro‑
floxacin, were widely used, isolates with decreased sus‑
ceptibility to ciprofloxacin (DCS) appeared, and these 
strains have reached high levels in Central, South, and 
South East Asia.6 Infections caused by strains with 
DCS respond poorly to ciprofloxacin and ofloxacin, 
with prolonged recovery times and increased rates 
of clinical failure.7 The laboratory detection of DCS 
strains is problematic because they are still classified as 
susceptible.8 Isolates with DCS are usually resistant to 
the first generation quinolone, nalidixic acid, and this 
is a useful, but not 100% reliable, surrogate laboratory 
marker for resistance. In some areas of Asia, isolates 
that are fully resistant to ciprofloxacin have emerged 
at the same time as the proportion of MDR infections 
has declined.5 So, should fluoroquinolones continue to 
be used as a firstline treatment for enteric fever?
The systematic review and meta‑analysis by Thaver 
and colleagues compares the effectiveness of fluoqui‑
nolones, chloramphenicol, ceftriaxone, cefixime, and 
azithromycin for treating enteric fever.4 Only 21 of 70 
trials were of sufficient quality to be included; many 
included small numbers of patients, and few trials were 
in children. In adults, fluoroquinolones significantly 
reduced clinical relapse compared with chloramphen‑
icol (odds ratio 0.14, 95% confidence interval 0.04 
to 0.50), clinical failure and relapse when compared 
with cefixime (0.05, 0.01 to 0.24), and clinical failure 
compared with ceftriaxone (0.08, 0.01 to 0.45). The 
fluoroquinolones significantly shortened fever clear‑
ance times compared with all three antibiotics. No tri‑
als compared fluoroquinolones with chloramphenicol 
or ceftriaxone in children, although in one trial fever 
clearance time was significantly shorter with ofloxacin 
than with cefixime. Oral azithromycin and the newer 
generation fluoroquinolone gatifloxacin were both 
effective against infections with DCS isolates.9‑12
Ciprofloxacin or ofloxacin remain the best choice 
for patients with enteric fever in areas where isolates 
with DCS are uncommon, such as in Africa, South 
America, and Central America. Concern that wide‑
spread use of ciprofloxacin in these areas will lead 
to the emergence of isolates with DCS highlights the 
need to understand the factors that determine this. Is 
it because the ciprofloxacin dose is too low, the dura‑
tion of treatment is too short, or because the lack of a 
satisfactory diagnostic test means that ciprofloxacin is 
used indiscriminately in all patients with fever?
For enteric fever acquired in many parts of Asia, 
more than 90% of isolates have DCS so ciprofloxacin 
and ofloxacin should be avoided. Azithromycin, gati‑
floxacin, or ceftriaxone can be used when MDR or 
DCS isolates are common. Resistance to ceftriaxone 
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and azithromycin is rarely reported, but isolates that 
are fully resistant to ciprofloxacin are now being 
detected in India, and gatifloxacin may not work for 
these infections. Combinations of these drugs are 
being used, but evidence for the effectiveness of this 
strategy is lacking.12
High quality adequately powered multicentre 
clinical trials are needed to compare these treatment 
options for enteric fever. Trials should include children 
and ambulatory patients and be completed quickly 
enough to influence clinical practice in the face of 
rapidly changing resistance patterns. Finally, preven‑
tion should not be forgotten, nor should the potential 
use of vaccination in areas where the disease burden 
is high and drug resistance is  common.
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changing the face of whistleblowing
statutory protection, regulatory support and culture change are needed
A decade after the scandal at Bristol Royal Infirmary1 
whistleblowing is still hazardous to whistleblowers. A 
whistleblower is a person who informs on another or 
makes public disclosure of corruption or wrongdo‑
ing. Margaret Haywood was struck off by the Nursing 
and Midwifery Council (NMC) after exposing poor 
standards of care at Brighton and Sussex University 
Hospitals NHS Trust.2 At the same time, prominent 
individuals have complained that  whistleblowing 
was inadequate at Mid‑Staffordshire NHS Founda‑
tion Trust,3 which has been widely reported in terms 
of hundreds of unnecessary deaths.4 What is the 
problem?
Most patients would surely expect doctors gener‑
ally to protect them from potential harm; doing so 
has been a key part of medical ethics for centuries. 
The General Medical Council (GMC) stipulates a 
professional ethical duty to raise concerns.5 Doctors 
and other healthcare staff owe their patients a duty 
of care. Failure to protect patients from harm may 
breach this duty, and resulting injury may give rise 
to civil and criminal legal liability. An NHS doc‑
tor is likely to have a contractual duty to participate 
in clinical governance procedures, which should 
include systems for raising concerns, and guidance 
on how to proceed when appropriate action is not 
taken. How often such systems exist in practice is 
unknown. Appropriate documented warnings to 
employers about threats to patient safety should pro‑
tect individuals from liability.6 The warnings should 
comply with local policy (where it exists), go through 
the proper channels (not through the media at an 
early stage), and be documented in writing.
Where governance procedures work smoothly, 
the term whistleblowing may be misleading. It sug‑
gests an escalated disclosure because appropriate 
action has not yet been taken. Careful consideration 
is  necessary before whistleblowing, which too often 
harms the whistleblowers themselves. The concerns 
of Dr Stephen Bolsin, the Bristol  whistleblower, about 
unsafe children’s heart surgery, were “cavalierly dis‑
missed,” his career stalled, and he now works on the 
other side of the world.7
Whistleblowers may be made to feel that they are 
the problem. More seriously, they may find them‑
selves the subject of retaliatory complaints and disci‑
plinary action. Wilmshurst reports that in one case of 
research fraud, whistleblowers were “advised to keep 
quiet or their careers would suffer.”8 He found that 
when he made one complaint to the GMC, it gave 
priority to investigating him for disparagement. He 
also discovered that his defence body was instrumen‑
tal in pressurising him to drop his concerns about 
another case of research fraud. The chairman of the 
BMA recently described “a culture of threats and 
bullying that stops whistle‑blowing.”9 It is no surprise 
that whistleblowers can be reluctant.
Limited protection for whistleblowers is afforded 
by the Public Interest Disclosure Act 1998 (PIDA 
1998), which “renders void contractual duties of 
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 confidentiality between employer and employee to 
the extent that they preclude the worker from mak‑
ing a ‘protected disclosure’. A protected disclosure is 
a disclosure which is not itself a criminal offence but 
which raises legitimate concerns about the employer’s 
business and is made in good faith through appropri‑
ate channels.”
Some believe that the protection the act affords 
is inadequate, and that it did not help the Bristol 
whistleblower.7 PIDA 1998 took effect via amend‑
ments to the law of unfair dismissal and there are, 
arguably, inadequacies in its operation. The act has 
influenced the development of policies on disclosures 
in the public interest by NHS trusts, although it is not 
clear how effective these are in affording protection 
to whistleblowers or the public interest. Would‑be 
whistleblowers should seek advice from their defence 
bodies, and possibly the BMA or Public Concern at 
Work (www.pcaw.co.uk/individuals/helpline.htm).
The document “Blowing the whistle” offers rel‑
evant and practical guidance.10 Of particular impor‑
tance is the need for whistleblowers to protect their 
own position. This includes careful documentation 
and “playing by the rules”—that is, adhering to the 
employer’s stated policy as far as possible. The 
Brighton whistleblower was open to NMC disci‑
plinary proceedings because she breached patient 
confidentiality and did not exhaust internal systems 
for raising concerns before releasing details to the 
media. The document also lists techniques used to 
discredit whistleblowers.
Concerning Mid‑Staffordshire NHS Trust, the 
chairman of the Healthcare Commission indicated 
that warnings existed about some of its problems for 
years before the problems became publicly known.11 
Why should staff accept the risks of whistleblowing 
if warnings are ignored?
The chairman of the Care Quality Commission has 
criticised staff at Mid‑Staffordshire NHS Trust and 
elsewhere for operating in a “culture of silence.”9 But 
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With the United Kingdom general election less than 
a year away and opinion polls showing the Conserva‑
tive Party well ahead of the Labour Party, there is 
increasing interest in the opposition’s health policies 
and their implications for the NHS.
The broad direction of the Conservatives’ thinking 
has been set out in a series of policy documents pub‑
lished in the period since David Cameron’s election 
as leader of the party in 2005.1 At the heart of this 
thinking is continuing support for a universal, com‑
prehensive, tax funded NHS, alongside plans that are 
both different from and similar to those pursued by 
the Labour government.
One of the principal differences concerns the 
 Conservatives’ commitment to distancing politicians 
from the day to day running of the NHS. This aim 
will be achieved through the establishment of an inde‑
pendent board made up of the NHS chief executive, 
his senior colleagues, and lay people serving in a non‑
executive capacity. The board will lead the manage‑
ment of the NHS within a framework of objectives set 
by the government and will report to parliament.
The creation of an NHS board is intended to enable 
the Department of Health to concentrate on public 
health issues in support of the stated aim of focusing 
on health outcomes rather than centrally imposed 
targets relating to clinical processes. This aim derives 
from the aspiration to return power to front line staff, 
the commission’s plan to assess progress at Stafford 
does not mention whistleblowers. The secretary of 
state for health has stated: “I do not understand why 
clinicians whose primary role is the safety of their 
patients are somehow concerned about whistleblow‑
ing.”12
 Several measures should be considered, includ‑
ing greater statutory protection, more support from 
regulatory bodies, and, above all, a culture change to 
encourage whistleblowing. A start would be for those 
in official positions to recognise the risks of whistle‑
blowing. Then they might begin to limit the damage 
wrought by the next Bristol, Brighton, and Stafford, 
scandals which are probably already happening.
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including doctors, by bringing an end to the micro‑
management of health care.
In the case of primary care, the Conservatives say 
they will renegotiate the contract of general medical 
services in order to facilitate a simplified quality and 
outcomes framework, the delivery of improved out of 
hours services, and extended access to services. These 
proposals echo loudly the policies being pursued by 
the current government, as do the Conservatives’ 
commitments to increasing the choices available to 
patients and offering individual budgets to people 
with long term conditions.
These commitments signal that the Conservatives 
will use markets rather than targets to improve perform‑
ance. In so doing, they will take further and faster the 
policies initiated under Tony Blair that have resulted 
in the introduction of NHS Foundation Trusts, the use 
of independent sector providers to treat NHS patients, 
and the system of payment by results under which 
money follows patients to the hospitals of their choice. 
And as Andrew Lansley, the shadow secretary of state 
for health, set out in a recent speech, the Conservatives 
will also make renewed efforts to collect and publish 
information about the performance of providers to sup‑
port patient choice.2
The many similarities between the health policies 
of the opposition and those of the government should 
come as no surprise given that the Labour government 
has pursued market based reforms for almost a decade. 
The main challenge for the Conservatives will be to 
show that their policies are ready for implementation 
if they are elected into office.
This challenge takes on added force in the light of 
independent assessments indicating that Labour’s poli‑
cies on choice and competition have had little impact to 
date.3 The improvements in NHS care made in the last 
decade, such as major reductions in the time patients 
wait for treatment, have been driven largely by “tar‑
gets and terror”—the very approach the Conservatives 
reject—together with increased spending.4
The reason that choice and competition have not 
made much impact derives from the difficulties that 
exist in applying market principles to health care. The 
onus is therefore on the Conservatives to explain how 
their version of competition will be more successful 
than the current government’s approach. Three issues 
in particular need to be clarified.
The first issue is the opposition’s proposal that gen‑
eral practitioners should hold budgets with which to 
commission services for their patients. This proposal 
is the Conservatives’ alternative to practice based 
commissioning, a policy that has failed to achieve the 
enthusiastic engagement of general practitioners on any 
significant scale.5 On the basis of the detail provided so 
far—essentially that budgets will be real and practices 
will be allowed to invest savings in providing further 
NHS services—there is no reason to believe that gen‑
eral practitioner budget holding will prove to be any 
more effective than practice based commissioning. The 
Conservatives urgently need to explain how they will 
motivate family doctors to commission services, an 
objective that Labour has yet to achieve.
The second issue concerns the role of primary care 
trusts as commissioners of services alongside general 
practitioner budget holders. The recent assessment of 
the performance of primary care trusts on the world 
class commissioning competences developed by the 
government showed that all trusts have much work 
to do in order to negotiate on equal terms with health 
care providers.6 With research evidence demonstrating 
that no system does healthcare commissioning consist‑
ently well,7 the Conservatives have a tough task on their 
hands to show that they can do better than Labour.
The third issue relates to healthcare providers who 
fail to compete successfully and how they will be han‑
dled. Competition in health care cannot be effective 
unless there is a real possibility of provider failure and, 
ultimately, exit from the market. The reluctance to 
allow providers to fail and, consequently, to accept a 
reduction in the public’s access to services has charac‑
terised past attempts by both the Conservatives and 
Labour to introduce market principles into the NHS. 
When politics and markets collide, politics usually win 
out. The Conservatives need to demonstrate that com‑
petition will be allowed to run its course, even at the 
risk of political unpopularity.
These points suggest that a degree of healthy scep‑
ticism is needed about the extent to which policies 
developed in opposition will be carried into practice. 
The political class in Britain today has little experi‑
ence outside politics, meaning that its members are 
often ill equipped to take up the reins of power and 
lead the reform of major public services like the NHS. 
This point is well illustrated by the frequent changes 
of direction in health policy made by the current 
Labour government.8 There is no reason to believe 
that politicians of other parties will fare any better.
Having set out a broad outline of their health pol‑
icy, the Conservatives now need to add the missing 
detail if they are to justify their claim to be a credible 
government in waiting. At a time when trust in politi‑
cians is at low ebb, the public has a right to expect full 
disclosure of policy intentions and detailed plans for 
implementation as the election draws closer.
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Professor Sir Muir Gray, in his book Evidence-based Health-
care1 tells the old joke about the epidemiologist up in 
court on a serious charge. “How do you plead? Guilty 
or not guilty?” asks the judge. “I don’t know: I haven’t 
heard the evidence yet.”
Recent events bring comedy, evidence, and law 
together as Ricky Gervais, Richard Dawkins, and Sir Iain 
Chalmers join together in a campaign that weds scientific 
rigour to free expression. On Wednesday of this week, 
leading academics, publishers, journalists, performers, cli‑
nicians, and scientists issued a public statement2 backing 
science writer Simon Singh in  his application to appeal 
against a libel judgment in the High Court. They fear that 
this judgment—if upheld—would have major implications 
for the ability of scientists, researchers, and other com‑
mentators freely to engage in robust criticism of scientific, 
and indeed purportedly scientific, work.
Singh, well‑known for his books on Fermat’s last theo‑
rem and the big bang, wrote an article on 19 April 2008 
in the Guardian newspaper criticising claims made by 
chiropractors about the efficacy of spinal manipulation in 
dealing with childhood conditions such as asthma, colic, 
and ear infections, among others. He suggested there was 
“not a jot” of evidence to support such interventions for 
these ailments, and complained that the British Chiro‑
practic Association “happily promotes bogus treatments”. 
The British Chiropractic Association has sued for libel.
On 7 May 2009, Mr Justice Eady issued a ruling3 on 
two preliminary matters. First, on the question of what 
meaning to give to the words in Singh’s article, he upheld 
the assertion of the British Chiropractic Association that 
the words meant that it knowingly promoted a treatment 
that they knew to be a sham. An alternative meaning—
more helpful to the defence—might be that the associa‑
tion was promoting something that, although ineffective, 
it sincerely believed to be effective. This would not 
carry the same implication of dishonesty. Second, and 
as a consequence of the first, the judge decided that the 
words represented a statement of verifiable fact, and that 
Singh therefore could not benefit from a “fair comment” 
defence. Singh has stated that, under the judge’s interpre‑
tation, it would be difficult for him to win the case.
There have been several cases where individuals and 
commercial interests, including pharmaceutical compa‑
nies, have sought to prevent the publication in scientific 
journals of opinions that they believe to be defamatory. 
By their very nature, examples of such censorship are not 
readily apparent to readers. 
Scientific publishers are subject to the same libel 
laws as everyone else. They struggle to find the right 
balance between a “safe” approach that amends or 
withdraws a proposed publication under threat of 
legal action and a more “courageous” one that seeks to 
protect the right of scientists and clinicians to engage 
in robust criticism of research work, pharmaceutical 
products, or medical devices.
What Singh’s case reinforces is the increasing recogni‑
tion that the libel laws in England and Wales give major 
advantages to the plaintiff, leading to “libel tourism,” 
with libel cases being brought by foreign business peo‑
ple against authors, themselves often also based abroad, 
in the courts of London. The jurisdictional reach is then 
justified on the basis of a handful of copies of the author’s 
work having been sold in England, or on its being avail‑
able on the internet. The advantages to the plaintiff under 
English law include a reversal of the usual burden of proof 
and a more limited range of defences being available than 
elsewhere, especially in respect of public interest.
The House of Commons, despite its current travails, 
has at least found time to attend to this matter, both in 
debate4 and in current enquiry by the Culture Media and 
Sport Select Committee.5
However, it is not clear that the government has any 
intention of changing the law—as can be seen from secre‑
tary of state for justice Jack Straw’s evidence to the com‑
mittee’s inquiry.6 All the government is carrying out at 
present is a review of the costs of defending defamation 
cases,7 but it has also suggested a review of libel law and 
the internet.6 The UK parliament is notoriously slow to 
protect free speech, given, for example, that it took cen‑
turies before the law of blasphemous libel was abolished 
last year.8 Indeed only this week I, along with free speech 
advocates, held a meeting with the same justice secretary 
to press him to abolish the ancient laws of seditious libel 
and criminal defamation—neither of which allow truthful‑
ness of the publication to be a full defence to the charge.
It is remarkable that the plaintiffs in this case are rep‑
resentatives of healthcare practitioners, who could, one 
would expect, make their case in peer reviewed scientific 
literature as well as through the usual letters columns 
of whatever newspaper they believe has treated them 
unfairly. Resorting to litigation against a writer, rather than 
the writer’s publisher, gives the impression that the British 
Chiropractic Association is seeking to “chill” criticism of 
the treatments that it promotes, or of the practitioners who 
make efficacy claims about such treatments.
It is hard to imagine the British Medical Association, 
even at its most reactionary, bringing libel proceedings 
against a commentator for deprecating the good name 
of doctors in its columns. If it did, neither the British 
Medical Association nor the Daily Mail would ever be 
out of the courts.
The fundamental point is that it is essential in the scien‑
tific sphere, and in particular in the world of medicine, for 
claims of efficacy to be subject to the most stringent exam‑
ination and criticism. In the field of health care, the con‑
sumer is particularly vulnerable to false promises of cure 
or symptomatic relief, and all practitioners—especially 
those in the private sector—need to be able to justify their 
claims in a transparent and scientific way. If that debate 
is chilled, then the medical profession, patients’ interests, 
and scientific discourse are severely undermined.
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